Hepatitis B virus genetics and drug resistance study
Part of Digestive system, Infections clinical trials.
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hepatitis B (positive for hepatitis B surface antigen).
- You must have your full medical information and stored blood or liver tissue samples available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This study looks at people with chronic hepatitis B who are also diagnosed with metabolic syndrome (a cluster of issues like belly fat, high blood pressure, abnormal cholesterol, or high blood sugar). It aims to see how these health factors may change how well the first hepatitis B antiviral medication works.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
This trial checks if certain hepatitis B virus mutations can cause resistance to entecavir, a common treatment. It looks at two groups: people who have never been treated and those who have taken lamivudine before.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.